Home Cart Sign in  
Chemical Structure| 944842-54-0 Chemical Structure| 944842-54-0

Structure of Decernotinib
CAS No.: 944842-54-0

Chemical Structure| 944842-54-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Decernotinib is a selective JAK3 inhibitor with Ki value of 2.5nM, with >4-fold selectivity over JAK1, JAK2, and TYK2 with Ki values of 11nM, 13nM and 13nM, respectively.

Synonyms: VX-509; VRT-831509; Adelatinib.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Decernotinib

CAS No. :944842-54-0
Formula : C18H19F3N6O
M.W : 392.38
SMILES Code : CC[C@@](C)(NC1=NC(C2=CNC3=NC=CC=C32)=NC=C1)C(NCC(F)(F)F)=O
Synonyms :
VX-509; VRT-831509; Adelatinib.
MDL No. :MFCD27987896
InChI Key :ASUGUQWIHMTFJL-QGZVFWFLSA-N
Pubchem ID :59422203

Safety of Decernotinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Decernotinib

epigenetics
RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • JAK1

    JAK1, Ki:11 nM

    JAK1, IC50:11 nM

  • JAK3

    JAK3, Ki:2.5 nM

  • Tyk2

    TYK2, Ki:13 nM

  • JAK2

    JAK2, Ki:13 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
HepaRG cells 40 µM 24 h Decernotinib inhibits the JAK/STAT signaling pathway, reversing OA-induced STAT3 activation and downregulation of CYP enzyme expression. PMC10000888

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01830985 Rheumatoid Arthritis PHASE2|PHASE3 COMPLETED 2025-07-14 Vertex Investigational Site, U... More >>pland, California, United States|Vertex Investigational Site, Fort Lauderdale, Florida, United States|Vertex Investigational Site, Venice, Florida, United States|Vertex Investigational Site, West Palm Beach, Florida, United States|Vertex Investigational Site, Canton, Georgia, United States|Vertex Investigational Site, Decatur, Georgia, United States|Vertex Investigational Site, Elizabethtown, Kentucky, United States|Vertex Investigational Site, Fredrick, Maryland, United States|Vertex Investigational Site, Lincoln, Nebraska, United States|Vertex Investigational Site, Rochester, New York, United States|Vertex Investigational Site, Greensboro, North Carolina, United States|Vertex Investigational Site, Duncansville, Pennsylvania, United States|Vertex Investigational Site, Charleston, South Carolina, United States|Vertex Investigational Site, Memphis, Tennessee, United States|Vertex Investigational Site, Katy, Texas, United States|Vertex Investigational Site, San Antonio, Texas, United States|Vertex Investigational Site, Webster, Texas, United States|Vertex Investigational Site, Spokane, Washington, United States|Vertex Investigational Site, Tallinn, Estonia|Vertex Investigational Site, Vilnius, Lithuania|Vertex Investigational Site, Pretoria, South Africa|Vertex Investigational Site, Stellenbosch, South Africa Less <<
NCT00789126 Healthy PHASE1 COMPLETED - Lenexa, Kansas, United States

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.55mL

0.51mL

0.25mL

12.74mL

2.55mL

1.27mL

25.49mL

5.10mL

2.55mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories